

The 12th International Forum of The Japanese Society of Gastroenterology

DAY2

Time & Date : 9 : 00~18 : 10, Friday, April 7, 2023

Place : Room 6 (1F, Conference Room 101-AB)

Main Theme : Therapeutic advances in gastrointestinal and hepatobiliary-pancreatic cancers
(Current medical management of gastrointestinal and hepatobiliary-pancreatic cancers)

1. Esophageal cancer

(9 : 00~10 : 10)

Moderator : Manabu Muto (Department of Clinical Oncology, Kyoto University, Japan)

- IF1-1 3D organoid system and a novel esophageal cancer cell-specific vulnerability
Hiroshi Nakagawa (Columbia University Digestive and Liver Diseases
Research Center, New York, USA)
- IF1-2 Intrinsic molecular subtype and prediction of response to chemoradiotherapy in
esophageal cancer
Manabu Muto (Department of Therapeutic Oncology, Graduate School of
Medicine, Kyoto University, Japan)
- IF1-3 Immuno-Oncology for esophageal cancer : updated in 2023
Ken Kato (Department of Head and Neck, Esophageal Medical Oncology,
National Cancer Center Hospital, Japan)

2. Latest Precision Oncology in Colorectal Cancer

(10 : 20~11 : 30)

Moderator : Takayuki Yoshino (Department of Gastroenterology and Gastrointestinal Oncology,
National Cancer Center Hospital East, Japan)

- IF2-1 The clinical application of “Liquid Biopsies” in the search of molecular targets
Tanios Bekaii-Saab (Mayo Clinic, U.S.A.)
- IF2-2 SCRUM-Japan Initiatives for Precision Oncology
Hideaki Bando (Translational Research Support Office, Division of Drug and
Diagnostic Development Promotion, Department for the
Promotion of Drug and Diagnostic Development, National
Cancer Center Hospital East, Japan)
- IF2-3 ctDNA and minimal residual disease detection in resectable colorectal cancer
Jeanne Tie (Department of Medical Oncology, Peter MacCallum Cancer
Centre, Melbourne, Australia)
- IF2-4 The CIRCULATE-JAPAN : Nationwide large-scale clinical trial for circulating
tumor DNA-guided management for colorectal cancer
Eiji Oki (Department of Surgery and Science, Graduate School of Medical
Sciences, Kyushu University, Japan)

3. Challenge for clinical issues in systemic therapy for hepatocellular carcinoma

(14 : 20~15 : 30)

Moderator : Masafumi Ikeda (Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East, Japan)

- IF3-1 Biomarker-based precision systemic therapy for advanced HCC
Takahiro Kodama (Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan)
- IF3-2 Current status and emerging issues of systemic therapy in patients with advanced hepatocellular carcinoma from Japanese real world practice
Sadahisa Ogasawara (Department of Gastroenterology, Graduate School of Medicine, Chiba University, Japan)
- IF3-3 Potential different immunotherapy efficacy among different etiology of HCC : are we ready to select regimens per etiology?
Changhoon Yoo (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea)
- IF3-4 Grow from mistakes—perspective of systemic therapy for HCC
Ann-Lii Cheng (Department of Medical Oncology, National Taiwan University Cancer Center, Taiwan)

4. Interventional EUS for pancreatobiliary diseases

(15 : 40~16 : 50)

Moderator : Ichiro Yasuda (Third Department of Internal Medicine, University of Toyama, Japan)

- IF4-1 Interventional EUS for pancreatobiliary diseases
Marc Giovannini (Paoli-Calmettes Institute, 232 Bd St-Marguerite 13273 Marseille cedex 9, France)
- IF4-2 Techniques and outcomes of EUS-guided gastroenterostomy
Anthony YB Teoh (Department of Surgery, The Chinese University of Hong Kong, Hong Kong, SAR)
- IF4-3 Technical tips for endoscopic ultrasound-guided biliary drainage to prevent adverse event and improve technical success rate
Takeshi Ogura (Endoscopy Center, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan)
- IF4-4 EUS-guided Celiac Plexus and Celiac Ganglia Neurolysis in Pancreatic Cancer
Shinpei Doi (Department of Gastroenterology, Teikyo University Mizonokuchi Hospital, Japan)

5. Topics of PRRT treatment for pancreatic gastrointestinal neuroendocrine tumors

(17 : 00~18 : 10)

Moderator : Tetsuhide Ito (Neuroendocrine Tumor Centre, Fukuoka Sanno Hospital, Japan)

- IF5-1 Predictive Factors for Resistant Disease with PRRT in Patients with Advanced Pancreatic Neuroendocrine Neoplasms
Lingaku Lee (Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.)
- IF5-2 Peptide Receptor Radionuclide Therapy for Unresectable Gastroenteropancreatic Neuroendocrine Tumors
Noritoshi Kobayashi (Department of Oncology, Yokohama City University Graduate School of Medicine, Japan)
- IF5-3 Current status and future strategies for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms
Nao Fujimori (Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University)